Alexander Munoz is a Senior Associate at F-Prime and works across the life sciences sub-sectors including therapeutics and medical technology. Prior to joining F-Prime, Alexander was a consultant at Boston Consulting Group, where he focused on biopharma diligence and commercial go-to-market strategy.
Alexander holds an MD from the Harvard-MIT Health Sciences & Technology (HST) program and an AB in applied mathematics and computer science from Harvard University.
Stephanie is a Venture Partner at F-Prime, advising portfolio companies in the USA, Europe, and India on their GTM strategies for sales, marketing, and customer success. She is also currently a Value Accelerator Operating Advisor at Goldman Sachs Asset Management, and previously held roles at Salesforce, Cordial Inc., Iterable, and Optimizely. Prior to her current roles, she was CMO at Gainsight where she successfully re-structured the Marketing and Business Development organizations ahead of the company’s $1.1bn exit in 2020, gaining valuable M&A experience along the way.
Stephanie brings more than 30 years of experience building and advising impactful and customer-centric sales and marketing teams at high-growth SaaS companies. She understands growth stage, scale-up, and established public company structure and culture, with knowledge of scaling companies from $3M ARR to more than $300M.
Stephanie is a graduate of the University of Northumberland, where she received a degree in Marketing (Hons).
Henry Trapnell joined F-Prime as a Director of Industry Networks to support the firm’s Tech Fund in the U.S. and Eight Roads Ventures abroad. He is a strong believer in the power of community to fuel business growth, and loves connecting portfolio company founders with corporate leaders to build symbiotic partnerships.
Prior to F-Prime, he helped lead digital go-to-market strategy at Google for the company’s hardware & services. He previously advised corporate executives on behalf of J.P. Morgan, where he developed a nuanced understanding of the intersection between emerging technologies, finance, and personal relationships.
Henry graduated from the Stanford Graduate School of Business and studied Economics and Chinese at Boston University. He also serves on the board of the Chestnut Hill Community Association in Philadelphia.
Michael is a Venture Partner at F-Prime focusing on FinTech and Saas companies. Previously, Michael was the 1st Finance & Ops hire at multiple venture backed SaaS startups (Affinity, Drawbridge) who built high performing Strategy, Finance, and Ops functions while raising $200M+ from leading venture firms. Earlier in his career, he helped found Fluid Financial, an on-demand invoice financing and cash flow management platform.
In recent years, Michael has leveraged his experience & expertise to serve as Advisor and Investor for numerous early stage startups.
Michael is a resident of Oakland and holds an B.A. in Economics from UC Berkeley.
Carolyn Haley joined F-Prime in 2023 where she serves as a Partner, Chief Operating Officer, and Chief Financial Officer and manages the administrative functions of the firm.
Prior to joining F-Prime, Carolyn was a partner and Global Head of Operations and Finance at GMO LLC where she was responsible for the firm’s strategic operating model and led various functions including Operations, Finance, Tax, Corporate Accounting, Enterprise Data Management and Investment Analysis. She also served as President and Trustee of the GMO Trust group of mutual funds, was a member of the Board of Directors for all of the firm’s subsidiaries and a served on several of the firm’s key governance committees, including the ESG and the Diversity, Equity and Inclusion Groups. Prior to GMO, Carolyn was Treasurer and Chief Compliance Officer at Tekla Capital Management (formerly Hambrecht & Quist Capital Management LLC). Prior to that, she was a senior manager with PricewaterhouseCoopers LLP where she served a broad range of clients in the asset management industry.
Ms. Haley earned her bachelor’s degree in Economics and History from Boston University, graduating magna cum laude, and her Masters of Science in Accounting from the Isenberg School of Management at the University of Massachusetts, Amherst. She is a Certified Public Accountant and a member of the American Institute of Certified Public Accountants and the Massachusetts Society of Certified Public Accountants.
Dr. John Shiver is a Special Advisor for F-Prime and is also Chief Strategy Officer at IGM ID a wholly owned subsidiary of IGM Biosciences. Established in 2021, IGM ID utilizes a proprietary IgM platform to treat and prevent infectious diseases. The potential utility of this platform for prevention and treatment of infectious diseases is supported by its recent application towards COVID-19 (Ku et al., Nature, published online 03 June 2021).
Prior to joining IGM ID, John was the SVP and Global Head of Vaccines R&D and a member of the Executive Leadership team for 8 years at Sanofi Pasteur, the largest company in the world devoted entirely to vaccines. He previously spent 22 years at Merck & CO where he held a series of senior leadership positions with his last position being VP and Head of Vaccines and Biologics Research. He was a member of Merck Vaccines Integrated Leadership Team and the Global Research Leadership Committee responsible for vaccine research, vaccine clinical assays and biomarkers, and biologics research, and siRNA technologies. Earlier in his career John spent five years at the National Cancer Institute, National Institutes of Health in Bethesda, MD.
John is a recognized expert and industry leader in vaccine and pharmaceutical research and development. He has guided numerous scientific teams that created novel vaccine and monoclonal antibody candidates to prevent or treat more than 40 infectious and non-infectious diseases, including HIV, influenza, HPV, RSV, CMV, pneumococcus, cancer, and asthma. He has collaborated with other senior leaders to secure the licensure of 14 pharmaceutical products spanning both vaccines and monoclonal antibodies, many of which were first- and/or best-in-class products addressing global infectious diseases. He also championed four acquisitions and three major collaborations to obtain new technologies or clinical candidates/products.
John is a Fellow of the American Academy of Microbiology and the International Society of Vaccines (ISV) and a member of multiple advisory boards, including the Board of Directors for the International AIDS Vaccine Initiative (IAVI), Board of Directors for Icosavax, and previously, the Executive Board of the International Society for Vaccines. He has also served on journal editorial boards, including Nature Partner Journals Vaccines and the Journal of Virology. He is the author of more than 150 articles, including 19 in Science, Nature, Cell, and the Proceedings of the National Academy of Sciences and is a co-author of 68 awarded patents. In addition, he is an Adjunct Professor at the University of Pennsylvania College of Medicine and has been recognized by the Financial Times.
John holds a PhD in Physical Chemistry from the University of Florida in Gainesville, FL and completed a postdoctoral fellowship in Biophysics at Purdue University in West Lafayette, IN. He also holds a Bachelor of Science degree in Chemistry and Mathematics from Wofford College in Spartanburg, SC.
Hannah is a Venture Partner at F-Prime and leads Business Development and Mortgage at Argyle. Previously she was on F-Prime’s tech investment team focused on early-stage FinTech investments. Prior to joining F-Prime, Hannah worked closely with startups in Johannesburg as an associate with Secha Capital, where she spent every day on the ground helping teams in Secha’s portfolio scale. She was a consultant with Bain & Company in Atlanta, where she served large tech clients and worked extensively with the Private Equity practice on deals spanning healthcare, e-commerce and industrials. She began her career working for non-profits in international development, where she saw firsthand the impact that innovative financial products can have on people’s lives. Hannah received her BA in Public Policy from Duke University.
Jillian Enos is Senior Director of Finance and joined F-Prime in April 2022. Prior to joining F-Prime, she worked at Charlesbank Capital Partners where she held the position of Valuations and Portfolio Reporting Manager. Jill also worked at PwC for six years, most recently as a Manager in their Assurance practice, where she was primarily focused on private equity and private credit fund clients.
Jill earned her BBA in Accounting from the Isenberg School of Management at University of Massachusetts, Amherst and is a certified public accountant in the state of Massachusetts.
Andrew Bognanni joined F-Prime in April 2022 to assist the finance and operations teams at the firm. Prior to joining F-Prime, he was employed by Standish Management where he held the position of Manager. He also worked at RSM in their audit practice. Andrew holds a M.S. in Accounting from Northeastern University.
Joshua Gray is Vice President and Associate General Counsel at Fidelity Investments and supports the F-Prime team on legal aspects of the firm’s operations, including portfolio company investments and exits, fund formation, ongoing fund administration, and day-to-day management company operations.
Josh joined Fidelity in 2022 from Nutter McClennen & Fish, where he was a Partner and a member of the Corporate and Transactions department. Josh also previously worked as an associate in the Technology and Life Sciences groups of the international law firm Goodwin Procter. He has over a decade of legal experience counseling venture capital and private equity firms, public and private companies, and entrepreneurs on a variety of matters, including company formation, equity and debt financings, mergers and acquisitions, strategic alliances, public offerings, securities law matters, corporate governance, intellectual property transactions, employment and equity compensation matters, and other general business matters. Over the course of his career, Josh has worked across a broad spectrum of industries, including life sciences, health care, medical devices, software, information technology, consumer goods and financial services.
Josh received his B.A., cum laude, from Syracuse University and his J.D. from New York University School of Law, where he was an Editor of the New York University Environmental Law Journal.
Josh is admitted to the Massachusetts bar.